2018
MicroRNA signatures discriminate between uterine and ovarian serous carcinomas
Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Human Pathology 2018, 76: 133-140. PMID: 29518404, DOI: 10.1016/j.humpath.2018.02.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinomaDiagnosis, DifferentialFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansMicroRNAsMiddle AgedNeoplasm GradingNeoplasms, Cystic, Mucinous, and SerousOligonucleotide Array Sequence AnalysisOvarian NeoplasmsPhenotypePredictive Value of TestsReproducibility of ResultsRetrospective StudiesTranscriptomeUterine NeoplasmsConceptsHigh-grade serous carcinomaOvarian serous carcinomaSerous carcinomaOvarian malignancyPrimary ovarian high-grade serous carcinomaOvarian high-grade serous carcinomaMiRNA signatureEndometrial serous carcinomaHigh-grade ovarian serous carcinomaUterine serous carcinomaEndometrial counterpartOvarian primaryTaqMan Low Density Array technologySynchronous primariesEndometrial cancerMetastatic tumorsCarcinomaPrimary siteSignature panelPathological determinationMicroRNA signatureSignificant discriminatory powerCancer cellsMalignancyLineage characteristics
2007
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions
Facchetti F, Lonardi S, Gentili F, Bercich L, Falchetti M, Tardanico R, Baronchelli C, Lucini L, Santin A, Murer B. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Archiv 2007, 451: 669-680. PMID: 17609977, DOI: 10.1007/s00428-007-0448-x.Peer-Reviewed Original ResearchMeSH KeywordsAscitic FluidBiomarkers, TumorBiopsyCarcinomaClaudin-4Diagnosis, DifferentialHumansImmunohistochemistryMembrane ProteinsMesotheliomaPeritoneumPleuraPleural EffusionConceptsDiagnosis of mesotheliomaSpindle cell neoplasmCell neoplasmsEpithelial neoplasmsFollicular dendritic cell sarcomaDendritic cell sarcomaBiphasic synovial sarcomaNeoplastic mesothelial cellsMetastatic tumor cellsSerosal metastasisPeritoneal biopsiesReactive effusionsMetastatic carcinomaSynovial sarcomaPrimary carcinomaCell sarcomaMesotheliomaMesothelial cellsMesothelioma diagnosisReactive mesotheliumUseful markerCarcinomaClaudin-4NeoplasmsCytological samplesLow-grade Fibromyxoid Sarcoma Presenting Clinically as a Primary Ovarian Neoplasm
Winfield HL, De Las Casas LE, Greenfield WW, Santin AD, McKenney JK. Low-grade Fibromyxoid Sarcoma Presenting Clinically as a Primary Ovarian Neoplasm. International Journal Of Gynecological Pathology 2007, 26: 173-176. PMID: 17413985, DOI: 10.1097/01.pgp.0000228145.36807.43.Peer-Reviewed Original ResearchMeSH KeywordsAdultDiagnosis, DifferentialFemaleFibromaHumansOvarian NeoplasmsRetroperitoneal NeoplasmsSarcomaConceptsLow-grade fibromyxoid sarcomaFibromyxoid sarcomaMesenchymal neoplasmsLeft-sided pelvic massDisease 11 monthsLeft ovarian massPrimary ovarian neoplasmsSecondary ovarian involvementMiddle-aged patientsBland spindle cell proliferationLeft hypogastric arteryMalignant mesenchymal neoplasmDeep soft tissuesSpindle cell proliferationRetroperitoneal sarcomaAbdominal painUrinary frequencyHypogastric arteryOvarian involvementSurgical resectionOvarian neoplasmsLeft ureterOvarian massesPelvic massFleshy mass
2004
Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Gokden M, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. British Journal Of Cancer 2004, 90: 1814-1824. PMID: 15208622, PMCID: PMC2409747, DOI: 10.1038/sj.bjc.6601791.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, PapillaryCells, CulturedCystadenocarcinoma, SerousDiagnosis, DifferentialFemaleFlow CytometryGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMiddle AgedOligonucleotide Array Sequence AnalysisOvarian NeoplasmsReceptor, ErbB-2Reverse Transcriptase Polymerase Chain ReactionUterine NeoplasmsConceptsUterine serous papillary carcinomaGene expressionOverexpressed genesSerous papillary carcinomaGene expression fingerprintGene expression profilingHuman genesC-erbB2 geneExpression fingerprintsMolecular basisExpression profilingPapillary carcinomaOligonucleotide microarraysExpression productsQuantitative RT-PCRGenesClinical tissue samplesProbe setsTwo-fold differenceMore effective treatment modalitiesEffective treatment modalitySerous papillary tumorsPlasminogen activator inhibitorDifferent biological behaviorDevelopment of novel